Buzdar Aman U (27 results)

Paperback. Condition: Very Good. Connecting readers with great books since 1972! Used books may not include companion materials, and may have some shelf wear or limited writing. We ship orders daily and Customer Service is our top priority.

Soft Cover. Condition: Very Good. Wraps have only light wear, spine is unbent. Pages are clean with no markings in text. Business name on fep. Size: 8vo - over 7¾" - 9¾" tall. Ex-Libris.

Trade Paperback. Condition: Very Good. Trade Paperback - VG - Book has slight warp otherwise clean and tight with light wear - Index.

Trade Paperback. Condition: USED Good.

Paperback. Condition: Very Good. Prompt Shipment, shipped in Boxes, Tracking PROVIDED*Very good, clean copy.

Paperback. Condition: Very Good +. No Jacket. 1997 Edition. Slight wear on book cover, secure binding, no noticed markings.

Condition: New.

Condition: As New. Unread book in perfect condition.

Condition: New. Breast cancer is one of the leading causes of cancer mortality in women worldwide. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to managing their disease. This pocketbook summarises the latest evidence-based information on the use of endocrine therapies in the management of breast cancer. Editor(s): Buzdar, Aman U. Series: Oxford Oncology Library. Num Pages: 128 pages, 10 black and white illustrations. BIC Classification: MJCL; MMG; MQC. Category: (P) Professional & Vocational. Dimension: 181 x 106 x 6. Weight in Grams: 112. . 2007. Paperback. . . . .…

hardcover. Condition: Very Good. Connecting readers with great books since 1972! Used books may not include companion materials, and may have some shelf wear or limited writing. We ship orders daily and Customer Service is our top priority.

Condition: New. In English.

Condition: New.

Condition: New. Breast cancer is one of the leading causes of cancer mortality in women worldwide. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to managing their disease. This pocketbook summarises the latest evidence-based information on the use of endocrine therapies in the management of breast cancer. Editor(s): Buzdar, Aman U. Series: Oxford Oncology Library. Num Pages: 128 pages, 10 black and white illustrations. BIC Classification: MJCL; MMG; MQC. Category: (P) Professional & Vocational. Dimension: 181 x 106 x 6. Weight in Grams: 112. . 2007. Paperback. . . . . Books ship from the US and Ireland.…

Paperback / softback. Condition: New. New copy - Usually dispatched within 4 working days.

Condition: As New. Unread book in perfect condition.

Condition: New. Satisfaction Guaranteed or your money back.

Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Condition: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Taschenbuch. Condition: Neu. Neuware - Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able to reduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging indications for the aromatase inhibitors are providing clinicans (and patients) with alternative treatment options with differing side effect profiles.Part of the Oxford Oncology Library, this pocketbook will summarise the latest evidence-based and practical information on the use of endrocrine therapies in the management of breast cancer (early stage, metastatic disease, and prevention of disease). With contributions from leading oncologists from the MD Anderson Cancer Center, the book covers the range of endocrine therapies currently available to clinicians including ovarian ablation, anti-estrogens, aromatase inhibitors, fulvestrant, progestins, androgens, and combination endocrine and chemotherapy. The book also includes useful chapters on the identification and optimal selection of patients for endocrine therapy as well as the role of endocrine treatments in the prevention of breast cancer. This book will serve as an invaluable reference for all health care professionals involved in the management of patients with breast cancer.…

Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Condition: New. pp. xvi + 624.

Condition: New. pp. xvi + 624 Illus.

Condition: New. pp. xvi + 624.

Hardcover. Condition: gut. 2002. Breast Cancer Management - Application of Clinical and Translational Evidence to Patient Care. -- Management von Brustkrebs: Anwendung klinischer und translationaler Evidenz auf die Patientenversorgung. In englischer Sprache. pages.

Condition: new. Questo è un articolo print on demand.

Paperback / softback. Condition: New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days.

Paperback. Condition: new. Paperback. Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromataseinhibitors are able to reduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging indications for the aromatase inhibitors are providing clinicans (andpatients) with alternative treatment options with differing side effect profiles.Part of the Oxford Oncology Library, this pocketbook will summarise the latest evidence-based and practical information on the use of endrocrine therapies in the management of breast cancer (early stage, metastatic disease, and prevention of disease). With contributions from leading oncologists from the MD Anderson Cancer Center, the book covers the range of endocrine therapies currentlyavailable to clinicians including ovarian ablation, anti-estrogens, aromatase inhibitors, fulvestrant, progestins, androgens, and combination endocrine and chemotherapy. The book also includes usefulchapters on the identification and optimal selection of patients for endocrine therapy as well as the role of endocrine treatments in the prevention of breast cancer.This book will serve as an invaluable reference for all health care professionals involved in the management of patients with breast cancer. Breast cancer is one of the leading causes of cancer mortality in women worldwide. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to managing their disease. This pocketbook summarises the latest evidence-based information on the use of endocrine therapies in the management of breast cancer. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.…